Premium
1,3 Bis‐(2 chloroethyl)‐1‐nitrosourea and streptozotocin chemotherapy
Author(s) -
Lokich Jacob J.,
Chawla Prem L.,
Frei Emil
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975173374
Subject(s) - nitrosourea , streptozotocin , chemotherapy , pharmacology , medicine , chemistry , diabetes mellitus , endocrinology
Streptozotocin (STZ) was combined with 1,3 bis‐(2 chloroethyl)‐1‐nitrosourea (BC NU) and with BCNU and 5‐fluorouracil (FU) in a 2‐ and 3‐drug clinical chemotherapeutic trial. The premise that STZ and BC NU are qualitatively different with regard to marrow suppression was the primary rationale of the study. The 2‐ and 3‐drug regimens were associated with a higher incidence of severe leukopenia and thrombopenia (47% and 100%, respectively) and a lower mean nadir for each (1,700/mm3 and 15,000/mm3) than the reported experience with single drug BCNU therapy. However, this synergism did not apply to therapeutic effects. The reasons for potentiation of marrow toxicity may be related to specific aspects of direct drug interaction as well as alterations in pharmacologic reactions.